Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Trial Profile

Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jul 2018

At a glance

  • Drugs Entinostat (Primary) ; Exemestane
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 03 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 05 Oct 2017 According to a Syndax Pharmaceuticals media release, first patient has been dosed.
    • 28 Sep 2017 New source identified and integrated(ClinicalTrials.gov NCT03291886)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top